Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Casopitant
Introduction
Overview
Overview
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]
References
References
- ↑ Lohr L (2008). “Chemotherapy-induced nausea and vomiting”. Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
- ↑ “GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa” (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.
Template:Antiemetics and antinauseants Template:Antidepressants Template:Anxiolytics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]